Identifying markers to predict which ductal carcinoma in situ may become invasive
Mapping ductal carcinoma in situ in space and time to reveal biomarkers that can predict invasive risk
This study is looking at a type of non-invasive breast cancer called DCIS to find clues that can help doctors know which cases might turn into more serious cancer, so they can create better, more personalized treatment plans for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Flanders Interuniv Inst Biotechnology NIH-funded |
| Lab location | 1 site (Gent, Belgium) |
| Project ID | NIH-11067856 on NIH RePORTER |
What this research studies
This research investigates ductal carcinoma in situ (DCIS), a non-invasive breast cancer, to identify biomarkers that can predict which cases may progress to invasive breast cancer. The study utilizes a unique living biobank of patient-derived xenograft models to observe the natural progression of DCIS over time. By analyzing various molecular subtypes and growth patterns, the research aims to improve understanding of DCIS dynamics and reduce unnecessary treatments for patients. This approach could lead to more personalized treatment plans based on individual risk assessments.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ductal carcinoma in situ who are currently facing treatment decisions.
Not a fit: Patients with invasive breast cancer or those who do not have a diagnosis of ductal carcinoma in situ may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce overtreatment and associated side effects for women diagnosed with DCIS.
How similar studies have performed: Other research has shown promise in using biobank models to study cancer progression, suggesting that this approach could yield valuable insights.
Where this research is happening
Gent, Belgium
- Flanders Interuniv Inst Biotechnology — Gent, Belgium (Active)
Researchers
- Principal investigator: Scheele, Colinda — Flanders Interuniv Inst Biotechnology
- Study coordinator: Scheele, Colinda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.